Medtronic says approval for Covidien deal 'progressing' Medtronic (MDT) CEO Omar Ishrak said on CNBC that the regulatory approval process for the closure of its Covidien (COV) is "progressing." Ishrak expects the deal to close at the end of this year or early next year. Shares of Covidien are off their lows of the day, but remain down 2% to $85.02 in afternoon trading.
Medtronic begins enrollment in feasibility study of Valiant Mona LSA system Medtronic announced the start of a new feasibility study to evaluate the safety and effectiveness of the Valiant Mona LSA branch thoracic stent graft system, an investigational medical device designed to enable a completely endovascular solution for aortic aneurysms encroaching on the left subclavian artery. Cleveland Clinic cardiothoracic surgeon Dr. Eric Roselli successfully completed the first implant in the study on Thursday. He serves as the study's national primary investigator and receives consulting fees and honoraria for teaching from Medtronic. The study aims to enroll 24 subjects at up to seven sites in the United States. The purpose of the study is to characterize the safety and effectiveness of the investigational device acutely and at 30 days.
IBM Medtronic to partner to improve diabetes care IBM (IBM) and Medtronic (MDT) announced that they will work together to combine powerful analytics and cognitive computing with diabetes medical devices and health data to develop a new generation of personalized diabetes management solutions. People using Medtronic diabetes solutions could benefit from new solutions developed in collaboration with IBM's newly-formed Watson Health unit.